Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2022 Jan 1;139(1):21-30.
doi: 10.1097/AOG.0000000000004632.

Prenatal Nicotine or Cannabis Exposure and Offspring Neurobehavioral Outcomes

Marcela C Smid  1 , Torri D Metz, Gwen A McMillin, Lisa Mele, Brian M Casey, Uma M Reddy, Ronald J Wapner, John M Thorp, George R Saade, Alan T N Tita, Emily S Miller, Dwight J Rouse, Baha Sibai, Maged M Costantine, Brian M Mercer, Steve N Caritis; for the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) Maternal-Fetal Medicine Units (MFMU) Network*
Affiliations
Randomized Controlled Trial

Prenatal Nicotine or Cannabis Exposure and Offspring Neurobehavioral Outcomes

Marcela C Smid et al. Obstet Gynecol. .

Abstract

Objective: To study the association between nicotine or cannabis metabolite presence in maternal urine and child neurodevelopmental outcomes.

Methods: We conducted a secondary analysis of two parallel multicenter randomized controlled trials of treatment for hypothyroxinemia or subclinical hypothyroidism among pregnant individuals enrolled at 8-20 weeks of gestation. All maternal-child dyads with a maternal urine sample at enrollment and child neurodevelopmental testing were included (N=1,197). Exposure was urine samples positive for nicotine (cotinine) or cannabis 11-nor-9-carboxy-delta-9-tetrahydrocannabinol [THC-COOH]) or both metabolites. Primary outcome was child IQ at 60 months. Secondary outcomes included cognitive, motor and language, attention, behavioral and social competency, and differential skills assessments at 12, 24, 36, and 48 months. Quantile regression analysis was performed with confounder adjustment.

Results: Of 1,197 pregnant individuals, 99 (8.3%) had positive cotinine samples and 47 (3.9%) had positive THC-COOH samples; 33 (2.8%) were positive for both. Groups differed in self-reported race and ethnicity, education, marital status, insurance, and thyroid status. Median IQ was similar between cotinine-exposed and -unexposed children (90 vs 95, adjusted difference in medians -2.47, 95% CI -6.22 to 1.29) and THC-COOH-exposed and -unexposed children (89 vs 95, adjusted difference in medians -1.35, 95% CI -7.76 to 5.05). In secondary outcome analysis, children with THC-COOH exposure compared with those unexposed had higher attention scores at 48 months of age (57 vs 49, adjusted difference in medians 6.0, 95% CI 1.11-10.89).

Conclusions: Neither prenatal nicotine nor cannabis exposure was associated with a difference in IQ. Cannabis exposure was associated with worse attention scores in early childhood. Longitudinal studies assessing associations between child neurodevelopmental outcomes and prenatal nicotine and cannabis exposure with a focus on timing and quantity of exposure are needed.

Clinical trial registration: ClinicalTrials.gov, NCT00388297.

PubMed Disclaimer

Conflict of interest statement

Financial Disclosure This study was funded in part by the University of Utah School of Medicine H.A. and Edna Benning Presidential Endowment. Dr. Smid serves as a medical consultant for Gilead Science Inc for hepatitis C treatment in pregnancy. Dr. Metz reports receiving UpToDate royalties for two topics on VBAC, and serving as a medical consultant to Pfizer for design of a SARS-CoV-2 vaccination trial in pregnancy. Funds for Dr. Metz were paid to her institution from Pfizer for being a site PI for an RSV vaccine trial. Funds were paid to her institution from Gestvision (site PI for preeclampsia POC test). Dr. Metz and Smid also report money was paid to her institution from NIDA. Dr. Tita reports support from NIH/NCATS and money was paid to his institution from Pfizer for a vaccine study and the CDC. Dr. Miller reports money was paid to her institution from Pfizer as a site PI for a study on COVID vaccine in pregnancy. The authors did not report any potential conflicts of interest.

Figures

Figure 1:
Figure 1:
Population cohort. *Not mutually exclusive with THC and cotinine positive groups. THC-COOH, 11-nor-9-carboxy-delta-9-tetrahydrocannabinol.
See this image and copyright information in PMC

Comment in

References

    1. Jamal A, Phillips E, Gentzke AS, et al. Current Cigarette Smoking Among Adults - United States, 2016. MMWR Morb Mortal Wkly Rep. January 19 2018;67(2):53–59. doi:10.15585/mmwr.mm6702a1 - DOI - PMC - PubMed
    1. Wang TW, Asman K, Gentzke AS, et al. Tobacco Product Use Among Adults - United States, 2017. MMWR Morb Mortal Wkly Rep. November 9 2018;67(44):1225–1232. doi:10.15585/mmwr.mm6744a2 - DOI - PMC - PubMed
    1. Creamer MR, Wang TW, Babb S, et al. Tobacco Product Use and Cessation Indicators Among Adults - United States, 2018. MMWR Morb Mortal Wkly Rep. November 15 2019;68(45):1013–1019. doi:10.15585/mmwr.mm6845a2 - DOI - PMC - PubMed
    1. Kerr WC, Lui C, Ye Y. Trends and age, period and cohort effects for marijuana use prevalence in the 1984–2015 US National Alcohol Surveys. Addiction. March 2018;113(3):473–481. doi:10.1111/add.14031 - DOI - PMC - PubMed
    1. Steigerwald S, Wong PO, Cohen BE, et al. Smoking, Vaping, and Use of Edibles and Other Forms of Marijuana Among U.S. Adults. Ann Intern Med. December 18 2018;169(12):890–892. doi:10.7326/m18-1681 - DOI - PMC - PubMed

Publication types

Associated data

Grants and funding